Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.
Department of Food Sciences and Nutrition, Kyungpook National University, Daegu, Korea.
J Med Food. 2019 Sep;22(9):928-936. doi: 10.1089/jmf.2018.4383. Epub 2019 Aug 7.
Bangpungtongseong-san (BT), an oriental herbal medicine, is used to treat obesity in Korea and East Asia and its antiobesity effects have been examined by several researchers. However, the molecular mechanisms of the antihepatic steatosis effects of BT are unclear. In this study, we examined the effects of BT on obesity, particularly nonalcoholic fatty liver disease, by analyzing metabolic and transcriptional responses using mRNA-sequencing profiles. C57BL/6J mice were fed a high-fat diet (HFD) or HFD + BT (1.5%, w/w, BT) for 12 weeks. Phenotype characteristics were estimated, and the antiobesity mechanism was examined using mRNA sequencing transcriptomic profiles in HFD-induced obese mice. BT treatment ameliorated dyslipidemia and hepatic steatosis in HFD-induced obese mice and reduced body weight gain. The levels of hepatic lipotoxicity markers were significantly decreased, while hepatic antioxidant enzyme activities were augmented by BT compared with in the HFD group. BT attenuated HFD-induced fatty liver through transcriptional changes in the liver. BT treatment downregulated mitochondrial oxidative phosphorylation-related genes in the liver, suggesting improved mitochondrial function. BT treatment also decreased the hepatic fibrosis-related transcriptome. Our findings provide insight into the antiobesity effects of BT, an alternative oriental medicine, for treating obesity-related conditions. Metabolic and transcriptional responses to diet-induced obesity with BT treatment improved liver function.
邦蓬通生散(BT)是一种东方草药,用于治疗韩国和东亚地区的肥胖症,其抗肥胖作用已被多位研究人员研究过。然而,BT 对肝脂肪变性的抗作用的分子机制尚不清楚。在这项研究中,我们通过分析肥胖症,特别是非酒精性脂肪肝疾病的代谢和转录反应,使用 mRNA 测序图谱来研究 BT 的作用。C57BL/6J 小鼠用高脂肪饮食(HFD)或 HFD+BT(1.5%,w/w,BT)喂养 12 周。评估表型特征,并在 HFD 诱导肥胖小鼠中使用 mRNA 测序转录组图谱研究抗肥胖机制。BT 治疗可改善 HFD 诱导肥胖小鼠的血脂异常和肝脂肪变性,并减轻体重增加。BT 组肝脏脂毒性标志物水平显著降低,而抗氧化酶活性增强。BT 通过肝脏转录变化减轻 HFD 诱导的脂肪肝。BT 治疗下调肝脏中线粒体氧化磷酸化相关基因,表明改善了线粒体功能。BT 治疗还降低了肝纤维化相关的转录组。我们的研究结果为 BT(一种替代的东方药物)治疗肥胖相关疾病的抗肥胖作用提供了新的见解。BT 治疗对饮食诱导肥胖的代谢和转录反应改善了肝功能。